Publication date: Available online 22 September 2017
Source:Médecine et Maladies Infectieuses
Author(s): Y. Serour, M. Bendahmane, F. Abbou Baker, M. Medles, B. Moueddene, R. Kraiba
IntroductionPersistent high-risk HPV (HR-HPV) infection is associated with a greater risk of cervical cancer.Patients and methodsStatistical data on the prevalence of HR-HPV infections in the Algerian population is lacking. We conducted a prospective study of 300 women aged between 25 and 50 years, screened for cervical cancer from 2012 to 2015 in Sidi Bel Abbès, a western region of Algeria. We aimed to assess the reliability of the repeated use of the HC II test (three longitudinal HPV tests 9 months apart from each other) in diagnosing the persistence of HR-HPV infection.ResultsThe prevalence of HR-HPV infection was 7.33% and infected women were aged 37.9±3years. For 90.9% of HR-HPV-positive patients, the infection persisted for a mean of 18.5months [95% CI: 16.9–22.1months]. Among these patients, 55.55% developed CIN1 and 11.11% developed CIN2. The sensitivity of the HC II test was 81.74% [95% CI: 71.3–89.6] and its positive predictive value associated with abnormal cervical biopsy was 27.49% [95% CI: 16.0–33.33].ConclusionRepeating the HC II test is a good predictor for identifying women at high risk of cervical cancer.